A comparison of echocardiographic variables of right ventricular function with exercise capacity after bosentan treatment in patients with pulmonary arterial hypertension: Results from a multicenter, prospective, cohort study

Hyungseop Kim, Jin Bae Lee, Jae Hyeong Park, Byung Su Yoo, Jang Won Son, Dong Heon Yang, Bong Ryeol Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Bosentan reduces pulmonary arterial pressure and improves exercise capacity in patients with pulmonary arterial hypertension (PAH). However, there are limited data regarding the extent to which the changes in echocardiographic variables reflect improvements in exercise capacity. We aimed to assess the improvement of echocardiographic variables and exercise capacity after 6 months of bosentan treatment for PAH. Methods: We performed a prospective study from June 2012 to June 2015 in seven participating medical centers. Echocardiography, including tissue Doppler imaging (TDI) and the 6-minute walk test distance (6MWD), was performed at baseline and after 6 months of bosentan treatment. Results: We analyzed 19 patients with PAH: seven with congenital shunt, six with collagen vascular disease, and six with idiopathic PAH. After bosentan treatment, mean 6MWD increased by 50 meters. Right ventricle (RV) systolic pressure, tricuspid annular plane systolic excursion, myocardial performance index (MPI) derived from TDI (MPI-TDI) of RV and left ventricle (LV), RV fractional area change, and RV ejection fraction were significantly improved. In particular, the magnitude of RV and LV MPI-TDI showed good correlation with changes in the 6MWD. Conclusions: The magnitude of RV and LV MPI-TDI was strongly associated with improvements in exercise capacity.

Original languageEnglish
Pages (from-to)28-34
Number of pages7
JournalJournal of Clinical Ultrasound
Volume45
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Right Ventricular Function
Pulmonary Hypertension
Heart Ventricles
Cohort Studies
Prospective Studies
Exercise
Therapeutics
bosentan
Collagen Diseases
Vascular Diseases
Echocardiography
Arterial Pressure
Blood Pressure
Lung

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

@article{b1e068bf73e045a8bd5d8724a3d0525f,
title = "A comparison of echocardiographic variables of right ventricular function with exercise capacity after bosentan treatment in patients with pulmonary arterial hypertension: Results from a multicenter, prospective, cohort study",
abstract = "Purpose: Bosentan reduces pulmonary arterial pressure and improves exercise capacity in patients with pulmonary arterial hypertension (PAH). However, there are limited data regarding the extent to which the changes in echocardiographic variables reflect improvements in exercise capacity. We aimed to assess the improvement of echocardiographic variables and exercise capacity after 6 months of bosentan treatment for PAH. Methods: We performed a prospective study from June 2012 to June 2015 in seven participating medical centers. Echocardiography, including tissue Doppler imaging (TDI) and the 6-minute walk test distance (6MWD), was performed at baseline and after 6 months of bosentan treatment. Results: We analyzed 19 patients with PAH: seven with congenital shunt, six with collagen vascular disease, and six with idiopathic PAH. After bosentan treatment, mean 6MWD increased by 50 meters. Right ventricle (RV) systolic pressure, tricuspid annular plane systolic excursion, myocardial performance index (MPI) derived from TDI (MPI-TDI) of RV and left ventricle (LV), RV fractional area change, and RV ejection fraction were significantly improved. In particular, the magnitude of RV and LV MPI-TDI showed good correlation with changes in the 6MWD. Conclusions: The magnitude of RV and LV MPI-TDI was strongly associated with improvements in exercise capacity.",
author = "Hyungseop Kim and {Bae Lee}, Jin and Park, {Jae Hyeong} and Yoo, {Byung Su} and Son, {Jang Won} and Yang, {Dong Heon} and Lee, {Bong Ryeol}",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/jcu.22396",
language = "English",
volume = "45",
pages = "28--34",
journal = "Journal of Clinical Ultrasound",
issn = "0091-2751",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

A comparison of echocardiographic variables of right ventricular function with exercise capacity after bosentan treatment in patients with pulmonary arterial hypertension : Results from a multicenter, prospective, cohort study. / Kim, Hyungseop; Bae Lee, Jin; Park, Jae Hyeong; Yoo, Byung Su; Son, Jang Won; Yang, Dong Heon; Lee, Bong Ryeol.

In: Journal of Clinical Ultrasound, Vol. 45, No. 1, 01.01.2017, p. 28-34.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A comparison of echocardiographic variables of right ventricular function with exercise capacity after bosentan treatment in patients with pulmonary arterial hypertension

T2 - Results from a multicenter, prospective, cohort study

AU - Kim, Hyungseop

AU - Bae Lee, Jin

AU - Park, Jae Hyeong

AU - Yoo, Byung Su

AU - Son, Jang Won

AU - Yang, Dong Heon

AU - Lee, Bong Ryeol

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose: Bosentan reduces pulmonary arterial pressure and improves exercise capacity in patients with pulmonary arterial hypertension (PAH). However, there are limited data regarding the extent to which the changes in echocardiographic variables reflect improvements in exercise capacity. We aimed to assess the improvement of echocardiographic variables and exercise capacity after 6 months of bosentan treatment for PAH. Methods: We performed a prospective study from June 2012 to June 2015 in seven participating medical centers. Echocardiography, including tissue Doppler imaging (TDI) and the 6-minute walk test distance (6MWD), was performed at baseline and after 6 months of bosentan treatment. Results: We analyzed 19 patients with PAH: seven with congenital shunt, six with collagen vascular disease, and six with idiopathic PAH. After bosentan treatment, mean 6MWD increased by 50 meters. Right ventricle (RV) systolic pressure, tricuspid annular plane systolic excursion, myocardial performance index (MPI) derived from TDI (MPI-TDI) of RV and left ventricle (LV), RV fractional area change, and RV ejection fraction were significantly improved. In particular, the magnitude of RV and LV MPI-TDI showed good correlation with changes in the 6MWD. Conclusions: The magnitude of RV and LV MPI-TDI was strongly associated with improvements in exercise capacity.

AB - Purpose: Bosentan reduces pulmonary arterial pressure and improves exercise capacity in patients with pulmonary arterial hypertension (PAH). However, there are limited data regarding the extent to which the changes in echocardiographic variables reflect improvements in exercise capacity. We aimed to assess the improvement of echocardiographic variables and exercise capacity after 6 months of bosentan treatment for PAH. Methods: We performed a prospective study from June 2012 to June 2015 in seven participating medical centers. Echocardiography, including tissue Doppler imaging (TDI) and the 6-minute walk test distance (6MWD), was performed at baseline and after 6 months of bosentan treatment. Results: We analyzed 19 patients with PAH: seven with congenital shunt, six with collagen vascular disease, and six with idiopathic PAH. After bosentan treatment, mean 6MWD increased by 50 meters. Right ventricle (RV) systolic pressure, tricuspid annular plane systolic excursion, myocardial performance index (MPI) derived from TDI (MPI-TDI) of RV and left ventricle (LV), RV fractional area change, and RV ejection fraction were significantly improved. In particular, the magnitude of RV and LV MPI-TDI showed good correlation with changes in the 6MWD. Conclusions: The magnitude of RV and LV MPI-TDI was strongly associated with improvements in exercise capacity.

UR - http://www.scopus.com/inward/record.url?scp=84993985657&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84993985657&partnerID=8YFLogxK

U2 - 10.1002/jcu.22396

DO - 10.1002/jcu.22396

M3 - Article

C2 - 27619758

AN - SCOPUS:84993985657

VL - 45

SP - 28

EP - 34

JO - Journal of Clinical Ultrasound

JF - Journal of Clinical Ultrasound

SN - 0091-2751

IS - 1

ER -